Advanced Melanoma

Oncology
11
Pipeline Programs
9
Companies
10
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
5
1
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%
+ 9 programs with unclassified modality

On Market (1)

Approved therapies currently available

Immunocore
KIMMTRAKApproved
tebentafusp
Immunocore
Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]injection2022

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Immunocore
ImmunocoreOXFORDSHIRE, United Kingdom
2 programs
2
1
BrenetafuspPhase 31 trial
TebentafuspPhase 31 trial
Active Trials
NCT06112314Recruiting680Est. Oct 2027
NCT05549297Recruiting540Est. Jul 2028
Eikon Therapeutics
Eikon TherapeuticsCA - Millbrae
1 program
1
EIK1001Phase 2/31 trial
Active Trials
NCT06697301Recruiting740Est. Dec 2040
M&
Merck & Co.RAHWAY, NJ
2 programs
2
Combination of GEN0101 and PembrolizmubPhase 21 trial
Imprime PGGPhase 21 trial
Active Trials
NCT03818893Unknown46Est. Jun 2022
NCT02981303Completed64Est. Dec 2020
Genentech
GenentechCA - Oceanside
1 program
1
Autogene cevumeranPhase 21 trial
Active Trials
NCT03815058Completed131Est. Jan 2025
RAPT Therapeutics
RAPT TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
1
FLX475Phase 21 trial
Active Trials
NCT04894994TerminatedEst. Sep 2022
E
EisaiChina - Liaoning
1 program
1
lenvatinibPhase 2Small Molecule1 trial
Active Trials
NCT03776136Completed103Est. Oct 2023
Precision BioSciences
1 program
1
OPM-101Phase 1/21 trial
Active Trials
NCT07040436Not Yet Recruiting41Est. Dec 2027
Oncodesign Precision Medicine
1 program
1
OPM-101Phase 1/2
Bristol Myers Squibb
1 program
Nivolumab + RelatlimabN/AMonoclonal Antibody1 trial
Active Trials
NCT07079644Completed678Est. Mar 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ImmunocoreBrenetafusp
ImmunocoreTebentafusp
Eikon TherapeuticsEIK1001
RAPT TherapeuticsFLX475
Merck & Co.Combination of GEN0101 and Pembrolizmub
Eisailenvatinib
GenentechAutogene cevumeran
Merck & Co.Imprime PGG
Precision BioSciencesOPM-101
Bristol Myers SquibbNivolumab + Relatlimab

Clinical Trials (10)

Total enrollment: 3,023 patients across 10 trials

NCT06112314ImmunocoreBrenetafusp

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Start: Jun 2024Est. completion: Oct 2027680 patients
Phase 3Recruiting
NCT05549297ImmunocoreTebentafusp

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Start: Dec 2022Est. completion: Jul 2028540 patients
Phase 3Recruiting
NCT06697301Eikon TherapeuticsEIK1001

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Start: May 2025Est. completion: Dec 2040740 patients
Phase 2/3Recruiting
NCT04894994RAPT TherapeuticsFLX475

FLX475 in Combination With Ipilimumab in Advanced Melanoma

Start: Sep 2021Est. completion: Sep 2022
Phase 2Terminated
NCT03818893Merck & Co.Combination of GEN0101 and Pembrolizmub

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Start: Mar 2019Est. completion: Jun 202246 patients
Phase 2Unknown
NCT03776136Eisailenvatinib

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Start: Jan 2019Est. completion: Oct 2023103 patients
Phase 2Completed
NCT03815058GenentechAutogene cevumeran

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

Start: Dec 2018Est. completion: Jan 2025131 patients
Phase 2Completed
NCT02981303Merck & Co.Imprime PGG

Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

Start: Feb 2017Est. completion: Dec 202064 patients
Phase 2Completed
NCT07040436Precision BioSciencesOPM-101

Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1

Start: Sep 2025Est. completion: Dec 202741 patients
Phase 1/2Not Yet Recruiting
NCT07079644Bristol Myers SquibbNivolumab + Relatlimab

Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

Start: Nov 2024Est. completion: Mar 2025678 patients
N/ACompleted

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 3,023 patients
9 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)